Peptic Ulcers - Pipeline Review, H2 2016

Date: December 21, 2016
Pages: 58
Price:
US$ 2,000.00 US$ 1,600.00
Offer valid until June 2, 2017!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: PAE1C737956EN
Leaflet:

Download PDF Leaflet

Peptic Ulcers - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peptic Ulcers – Pipeline Review, H2 2016, provides an overview of the Peptic Ulcers (Gastrointestinal) pipeline landscape.

Peptic ulcers are open sores that develop on the inside lining of esophagus, stomach and the upper portion of small intestine. Symptoms include nausea or vomiting, unexplained weight loss, appetite changes and abdominal pain. Risk factors include smoking and alcoholism. Treatment includes antibiotic, acid blockers, antacids and proton pump inhibitors.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peptic Ulcers – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Peptic Ulcers (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peptic Ulcers (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Peptic Ulcers and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 3 and 11 respectively.

Peptic Ulcers (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peptic Ulcers (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Peptic Ulcers (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peptic Ulcers (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peptic Ulcers (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peptic Ulcers (Gastrointestinal)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peptic Ulcers (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peptic Ulcers (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Introduction
Global Markets Direct Report Coverage
Peptic Ulcers Overview
Therapeutics Development
Pipeline Products for Peptic Ulcers - Overview
Peptic Ulcers - Therapeutics under Development by Companies
Peptic Ulcers - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Peptic Ulcers - Products under Development by Companies
Peptic Ulcers - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Boryung Pharmaceutical Co Ltd
ChoDang Pharm Co Ltd
Daewoong Pharmaceutical Co Ltd
Kukje Pharmaceutical Industry Co Ltd
RaQualia Pharma Inc
Sequella Inc
Sinil Pharmaceutical Co Ltd
XuanZhu Pharma Co Ltd
Yooyoung Pharmaceutical Co Ltd
Peptic Ulcers - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(ecabet + ranitidine) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
(lansoprazole + omeprazole) - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
anaprazole sodium - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ASP-6537 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BGC-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cholesteryl glucoside - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-1386 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DWJ-206 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KJ-14001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMKS-005 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00000774 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SI-001002 SR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Potassium Transporting ATPase Alpha Chain 1 Inhibitor for Peptic Ulcers and Reflux Esophagitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules for Gastric Ulcers - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SQ-109 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
YYD-601 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptic Ulcers - Dormant Projects
Peptic Ulcers - Discontinued Products
Peptic Ulcers - Product Development Milestones
Featured News & Press Releases
Jul 17, 2013: Sihuan Pharmaceutical Secures SFDA Approval for Anaprazole Sodium Category 1.1 New Drug Clinical Studies
Dec 06, 2010: Sequella Wins FDA Approval To Begin Phase II Trial Of SQ109 In Helicobacter pylori-Associated Duodenal Ulcers
Mar 01, 2010: AstraZeneca Provides An Update On The Status Of Its Arrangements With Merck
Jan 07, 2010: AstraZeneca Reaches Agreements With Teva Pharmaceuticals Regarding Nexium And Prilosec US Patent Litigations
Apr 15, 2008: AstraZeneca Settles US Nexium Patent Litigation with Ranbaxy
Feb 28, 2008: AstraZeneca Provides An Update on the Status of its Arrangements With Merck & Co., Inc.
Dec 10, 2007: FDA Concludes There Is No Increased Risk Of Cardiac Events For Patients Treated With Omeprazole And NEXIUM (Esomeprazole Magnesium)
Jun 01, 2007: AstraZeneca’s Prilosec Patents Upheld By Court
Dec 12, 2003: Astrazeneca Prilosec Patents Upheld by Federal Appeals Court
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer 58

LIST OF TABLES

Number of Products under Development for Peptic Ulcers, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Peptic Ulcers - Pipeline by Astellas Pharma Inc, H2 2016
Peptic Ulcers - Pipeline by Boryung Pharmaceutical Co Ltd, H2 2016
Peptic Ulcers - Pipeline by ChoDang Pharm Co Ltd, H2 2016
Peptic Ulcers - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2016
Peptic Ulcers - Pipeline by Kukje Pharmaceutical Industry Co Ltd, H2 2016
Peptic Ulcers - Pipeline by RaQualia Pharma Inc, H2 2016
Peptic Ulcers - Pipeline by Sequella Inc, H2 2016
Peptic Ulcers - Pipeline by Sinil Pharmaceutical Co Ltd, H2 2016
Peptic Ulcers - Pipeline by XuanZhu Pharma Co Ltd, H2 2016
Peptic Ulcers - Pipeline by Yooyoung Pharmaceutical Co Ltd, H2 2016
Assessment by Monotherapy Products, H2 2016
Assessment by Combination Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Peptic Ulcers - Dormant Projects, H2 2016
Peptic Ulcers - Dormant Projects (Contd..1), H2 2016
Peptic Ulcers - Discontinued Products, H2 2016 51

LIST OF FIGURES

Number of Products under Development for Peptic Ulcers, H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Targets, H2 2016
Number of Products by Stage and Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Stage and Molecule Types, H2 2016
Skip to top


Gastric Ulcers - Pipeline Review, H2 2016 US$ 1,600.00 Sep, 2016 · 43 pages
Gastric Ulcers - Pipeline Review, H1 2017 US$ 1,600.00 Apr, 2017 · 42 pages
Corneal Ulcers - Pipeline Review, H2 2015 US$ 1,600.00 Dec, 2015 · 39 pages
Peptic Ulcers - Pipeline Insights, 2017 US$ 1,250.00 Jan, 2017 · 60 pages

Ask Your Question

Peptic Ulcers - Pipeline Review, H2 2016
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: